These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10497065)

  • 1. Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli.
    Cox GN; Pratt D; Smith D; McDermott MJ; Vanderslice RW
    Protein Expr Purif; 1999 Oct; 17(1):26-32. PubMed ID: 10497065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides.
    Nuttall SD; Rousch MJ; Irving RA; Hufton SE; Hoogenboom HR; Hudson PJ
    Proteins; 1999 Aug; 36(2):217-27. PubMed ID: 10398368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
    McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
    Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression, refolding, purification, molecular characterization, crystallization, and preliminary X-ray analysis of the receptor binding domain of human B7-2.
    Zhang X; Schwartz JC; Almo SC; Nathenson SG
    Protein Expr Purif; 2002 Jun; 25(1):105-13. PubMed ID: 12071705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B70 antigen is a second ligand for CTLA-4 and CD28.
    Azuma M; Ito D; Yagita H; Okumura K; Phillips JH; Lanier LL; Somoza C
    Nature; 1993 Nov; 366(6450):76-9. PubMed ID: 7694153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).
    Morton PA; Fu XT; Stewart JA; Giacoletto KS; White SL; Leysath CE; Evans RJ; Shieh JJ; Karr RW
    J Immunol; 1996 Feb; 156(3):1047-54. PubMed ID: 8557978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.
    Manzotti CN; Tipping H; Perry LC; Mead KI; Blair PJ; Zheng Y; Sansom DM
    Eur J Immunol; 2002 Oct; 32(10):2888-96. PubMed ID: 12355442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
    Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
    J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation.
    Cross AH; Girard TJ; Giacoletto KS; Evans RJ; Keeling RM; Lin RF; Trotter JL; Karr RW
    J Clin Invest; 1995 Jun; 95(6):2783-9. PubMed ID: 7539461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
    Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
    Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CTLA-4 structure and expression on human T cells.
    Lindsten T; Lee KP; Harris ES; Petryniak B; Craighead N; Reynolds PJ; Lombard DB; Freeman GJ; Nadler LM; Gray GS
    J Immunol; 1993 Oct; 151(7):3489-99. PubMed ID: 8397258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.
    Stamper CC; Zhang Y; Tobin JF; Erbe DV; Ikemizu S; Davis SJ; Stahl ML; Seehra J; Somers WS; Mosyak L
    Nature; 2001 Mar; 410(6828):608-11. PubMed ID: 11279502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80.
    Boulougouris G; McLeod JD; Patel YI; Ellwood CN; Walker LS; Sansom DM
    J Immunol; 1998 Oct; 161(8):3919-24. PubMed ID: 9780158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
    Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
    J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of CD80 and CD86 with CD28 and CTLA4.
    Ellis JH; Burden MN; Vinogradov DV; Linge C; Crowe JS
    J Immunol; 1996 Apr; 156(8):2700-9. PubMed ID: 8609386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation.
    Xu Z; Juan V; Ivanov A; Ma Z; Polakoff D; Powers DB; Dubridge RB; Wilson K; Akamatsu Y
    J Immunol; 2012 Nov; 189(9):4470-7. PubMed ID: 23018459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
    Freeman GJ; Lombard DB; Gimmi CD; Brod SA; Lee K; Laning JC; Hafler DA; Dorf ME; Gray GS; Reiser H
    J Immunol; 1992 Dec; 149(12):3795-801. PubMed ID: 1281186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
    Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
    Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
    Freeman GJ; Cardoso AA; Boussiotis VA; Anumanthan A; Groves RW; Kupper TS; Clark EA; Nadler LM
    J Immunol; 1998 Sep; 161(6):2708-15. PubMed ID: 9743327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.